Dermatology Times: Alphyn Expands Pipeline with Phase 2 Trial of Zabalafin Hydrogel for Molluscum Contagiosum by Marie Bosslett NEWS PROVIDED BY Alphyn Biologics February 19, 2026 Alphyn Biologics advances zabalafin hydrogel for MC, aiming for painless relief by clearing lesions and itch in pediatric patients. Read the Dermatology Times article here. CONTACTS Corporate: Neal Koller…
First Patients Dosed in Alphyn Biologics’ Phase 2 Trial of First-in-Class Topical Therapeutic for Molluscum Contagiosum NEWS PROVIDED BY Alphyn Biologics Feb 18, 2026, 07:30 ET New program expands pipeline derived from Alphyn’s proprietary multi-target drug platform ANNAPOLIS, Md., Feb. 18, 2026 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®,…
Masters of Pediatric Dermatology 2026 Poster Presentation: S. aureus Contribution to the Etiology of Pediatric Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics February 5, 2026, 00:00 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
Masters of Pediatric Dermatology 2026 Poster Presentation: Zabalafin, a Novel Topical Antiviral for the Treatment of Molluscum Contagiosum NEWS PROVIDED BY Alphyn Biologics February 5, 2026, 00:00 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline NEWS PROVIDED BY Alphyn Biologics Dec 12, 2025, 07:30 ET Financing funds the global Phase 2b clinical trial in atopic dermatitis and Phase 2 clinical program in molluscum contagiosum ANNAPOLIS, Md., Dec. 12, 2025 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing…